Immunoglobulin G2, Anti-(Human Cd19 (Antigen)) (Synthetic Human Monoclonal Medi-551 Heavy Chain), Disulfide With Synthetic Human Monoclonal Medi-551 .Kappa.-Chain, Dimer
Autoimmune Encephalitis
University of Utahmonoclonal_antibodyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 89/ 100
Competitive context
8 Active assets in the Autoimmune Encephalitis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cyclophosphamide Tongji Hospital | Phase 2 | BB |
Human Immunoglobulins University of Utah | Phase 2 | CCC |
Rituximab University of Cambridge | Phase 2 | CCC |
Fludarabine Tongji Hospital | Phase 1 | CCC |
Universal Cd19 Car-Γδt Cell Tongji Hospital | Phase 1 | CC |
View all 9 →
Same molecule, other indications
Immunoglobulin G2, Anti-(Human Cd19 (Antigen)) (Synthetic Human Monoclonal Medi-551 Heavy Chain), Disulfide With Synthetic Human Monoclonal Medi-551 .Kappa.-Chain, Dimer is also rated in:
chronic lymphocytic leukemia/small lymphocytic lymphomaDormant
B
Indicative · Phase 2
57 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →